Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up

Autor: Elisa Jacobsen Pulczynski, Mikkel Runason Simonsen, Outi Kuittinen, Unn-Merete Fagerli, Martin Erlanson, Øystein Fluge, Sirpa Leppä, Bjørn Østenstad, Alexander Fosså, Mikael Eriksson, Tarec El-Galaly, Hanne Kuitunen, Karin Papworth, Maria Ljungqvist, Martin B. Pedersen, Marjukka Pollari

Publikováno v: Haematologica, Vol 999, Iss 1 (2024)

Not available.

Externí odkaz: https://doaj.org/article/b356f734dc304e7dbf40d10412436a97

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Patients with Primary Central Nervous System Lymphoma Have High Levels of Soluble Programmed Cell Death Protein 1 in Their Pretherapeutic Cerebrospinal Fluid

Autor: Mette Bjerre, Rasmus Svane Ditlev Severinsen, Julie Bondgaard Mortensen, Christopher Vejgaard, Gorm von Oettingen, Francesco d'Amore, Eigil Kjeldsen, Michael Thorsgaard, Marie Beck Enemark, Elisa Jacobsen Pulczynski, Holger Jon Møller

Publikováno v: Blood. 138:1334-1334

§ s hared first authorship; §§ s hared last authorship Primary Central Nervous System Lymphoma (PCNSL) is a rare and aggressive non-Hodgkin lymphoma with limited treatment options and severe prognosis. It may display copy number abnormalities of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::87a2b1c8315ae77e52d62a75c8974326
https://doi.org/10.1182/blood-2021-144882

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

Autor: Tobias Pukrop, Francesco Pisani, Gerald Illerhaus, Franco Cavalli, Eleonora Minacapelli, Alessandro Levis, Jette Sønderskov Gørløv, Lorella Orsucci, Elisabeth Schorb, Paul La Rosée, Elisa Jacobsen Pulczynski, Francesco Angrilli, Stephan Stilgenbauer, Monica Balzarotti, Georg Hess, Alexander Röth, Jeffery Smith, Claire Hemmaway, Fiorella Ilariucci, Kim Linton, Stefan W. Krause, Alberto Fabbri, Andrés José Maria Ferreri, Mascha Binder, Kate Cwynarski, Maurilio Ponzoni, Jens Panse, Bernd Hertenstein, Martina Deckert, Valter Torri, Hans J. Schmoll, Monica Falautano, Alessandra Tucci, Ulrich Keller, Letterio S. Politi, Emanuele Zucca, Juergen Finke, Christopher P. Fox, Mathias J. Rummel, Giuseppina Cabras, Peter Johnson, Achille Ambrosetti, Michele Reni, Michael Pfreundschuh

Publikováno v: Ferreri, A J M, Cwynarski, K, Pulczynski, E, Fox, C P, Schorb, E, La Rosée, P, Binder, M, Fabbri, A, Torri, V, Minacapelli, E, Falautano, M, Ilariucci, F, Ambrosetti, A, Roth, A, Hemmaway, C, Johnson, P, Linton, K M, Pukrop, T, Sønderskov Gørløv, J, Balzarotti, M, Hess, G, Keller, U, Stilgenbauer, S, Panse, J, Tucci, A, Orsucci, L, Pisani, F, Levis, A, Krause, S W, Schmoll, H J, Hertenstein, B, Rummel, M, Smith, J, Pfreundschuh, M, Cabras, G, Angrilli, F, Ponzoni, M, Deckert, M, Politi, L S, Finke, J, Reni, M, Cavalli, F, Zucca, E, Illerhaus, G & International Extranodal Lymphoma Study Group (IELSG) 2017, ' Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma : results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial ', The Lancet Haematology, pp. 510-523 . https://doi.org/10.1016/S2352-3026(17)30174-6
International Extranodal Lymphoma Study Group (IELSG) 2017, ' Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma : results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial ', The Lancet Haematology, vol. 4, no. 11, pp. e510-e523 . https://doi.org/10.1016/S2352-3026(17)30174-6

Background The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a239047c9843fd82496a3344d9d5cc5b
http://hdl.handle.net/11562/969655

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Autor: Michele Reni, Mascha Binder, Angela Ferrari, Roberta Rudà, Ulrich Keller, Tobias Pukrop, Bernd Hertenstein, Georg Hess, Gerald Illerhaus, Peter Johnson, Stephan Stilgenbauer, Claire Hemmaway, Elisabeth Schorb, Paul La Rosée, Francesco Pisani, Jens Panse, Achille Ambrosetti, Monica Balzarotti, Franco Cavalli, Jürgen Finke, Kate Cwynarski, Emanuele Zucca, Martina Deckert, Andrés José Maria Ferreri, Alexander Röth, Alberto Fabbri, Valter Torri, Alessandro Levis, Alessandra Tucci, Letterio S. Politi, Elisa Jacobsen Pulczynski, Kim Linton, Stefan W. Krause, Christopher P. Fox, Maurilio Ponzoni, Hans J. Schmoll, Jette Sønderskov Gørløv

Publikováno v: Ferreri, A J M, Cwynarski, K, Pulczynski, L E S J, Ponzoni, M, Deckert, M, Politi, L S, Torri, V, Fox, C P, Rosée, P L, Schorb, E, Ambrosetti, A, Roth, A, Hemmaway, C, Ferrari, A, Linton, K M, Rudà, R, Binder, M, Pukrop, T, Balzarotti, M, Fabbri, A, Johnson, P, Gørløv, J S, Hess, G, Panse, J, Pisani, F, Tucci, A, Stilgenbauer, S, Hertenstein, B, Keller, U, Krause, S W, Levis, A, Schmoll, H J, Cavalli, F, Finke, J, Reni, M, Zucca, E, Illerhaus, G & International Extranodal Lymphoma Study Group (IELSG) 2016, ' Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma : results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial ', Lancet Haematol, vol. 3, no. 5, pp. e217-27 . https://doi.org/10.1016/S2352-3026(16)00036-3

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::551bfa68ef78715bcb0b03900a64fa2c
https://pubmed.ncbi.nlm.nih.gov/27132691